文献速递免疫规划妇幼与学校卫生卫生政策与健康促进

日本孕期百日咳疫苗接种的成本效果分析

Cost-effectiveness analysis of pertussis vaccination during pregnancy in Japan.
PubMed 文献 · Vaccine · 2018-07-21

该研究评估日本孕期母亲接种含无细胞百日咳成分疫苗(aP)预防新生儿和未接种婴儿百日咳的成本效果,采用决策树与马尔可夫模型,从社会视角计算增量成本效果比(ICER)。结果显示ICER为每获得一个质量调整生命年(QALY)9,149,317日元/83,176美元,增量QALY为0.0002802,其中79.5%来自婴儿。结论认为在日本该策略符合世界卫生组织(WHO)建议的「成本效果」标准(GDP的1至3倍)。

要点

  • 孕期母亲接种含aP疫苗可减少疾病治疗费用,但减少额不能抵消疫苗接种成本。
  • ICER为每QALY 9,149,317日元/83,176美元,增量QALY为0.0002802,79.5%来自婴儿。
  • 单因素敏感性分析显示发病率与每剂成本是影响ICER的两个主要变量。

核心结论

  • 在日本,孕期母亲接种含aP疫苗预防新生儿和未接种婴儿百日咳相关疾病,从社会视角看具有成本效果,符合WHO建议的「成本效果」标准(GDP的1至3倍)。
  • 百日咳预计于2018年被指定为法定报告传染病,当获得直接发病率数据时应重新分析。

研究设计与样本

  • 成本效果分析,采用决策树模型(婴儿)和马尔可夫模型(母亲),从社会视角比较孕期母亲接种策略与当前无接种策略。
  • 婴儿疫苗有效性持续时间设为单年,母亲为多年;母亲马尔可夫模型以一年为周期,运行至接种后第四年,基于疫苗有效性减弱。
  • 每剂疫苗接种成本假设为6000日元/54.5美元;婴儿百日咳存活者假设存活至其预期寿命。

主要发现

  • 孕期母亲接种策略减少疾病治疗费用,但减少额不能抵消疫苗接种成本。
  • 增量QALY为0.0002802,其中79.5%来自婴儿,其余来自母亲。
  • ICER为每QALY 9,149,317日元/83,176美元。
  • 单因素敏感性分析确定发病率和每剂成本是影响ICER的两个主要关键变量。

关键数值与推荐

  • ICER为每QALY 9,149,317日元/83,176美元。
  • 增量QALY为0.0002802,其中79.5%来自婴儿。
  • 每剂疫苗接种成本假设为6000日元/54.5美元。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Both re-emergence of pertussis outbreak among adolescents/adults and recent approval of the extended use of DTaP vaccine for boosting adolescents/adults against pertussis in Japan, have raised the possibility of using aP-containing vaccine in pregnant women to protect neonates and unvaccinated infants. There is a need, therefore, to evaluate the value for money of such possibility. METHODS: We evaluated the cost-effectiveness of conducting antepartum maternal vaccination (AMV) strategy in Japan. Considering the duration of vaccine effectiveness for infant (single year) and for mother (multiple years), the decision tree model and Markov model was adapted for infant and mother, respectively. Incremental cost-effectiveness ratio (ICER) compared with current no AMV strategy from societal perspective were calculated. The transition probabilities, utility weights to estimate quality-adjusted life year (QALY), and disease treatment costs were either calculated or extracted from literature. Costs per vaccination was assumed at ¥6000/US$54.5. Markov model for mothers with one-year cycle runs up to year four after vaccination, based on the waning of vaccine effectiveness. Infant who survived from pertussis was assumed to live until to his/her life expectancy. RESULTS: AMV strategy reduces disease treatment costs, while the reduction cannot offset the vaccination cost. Incremental QALYs were at 0.0002802, among them 79.5% were from infants, and others from mothers. ICER was ¥9,149,317/US$83,176 per QALY gained. One-way sensitivity analyses identified that the incidence rate and costs per shot were the two main key variables to impact the ICER. CONCLUSION: We found that vaccinating pregnant women with aP-containing vaccine to prevent neonatal and unvaccinated infants from pertussis-associated disease in Japan can be cost-effective from societal perspective, under the WHO-suggested "cost-effective" criteria (1 to 3 times of GDP). Pertussis is expected be designated as a notifiable disease in 2018, re-analysis should be conducted when straightforward incidence data is available.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Hoshi SL, Seposo X, Okubo I, et al. Cost-effectiveness analysis of pertussis vaccination during pregnancy in Japan. Vaccine. 2018. PMID: 30041878. doi:10.1016/j.vaccine.2018.07.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。